About
10.24HKD+0.31 +3.12%
Closed • Updated at 04:27 GMT+00:00Market Cap$946.34M
P/E Ratio95.34
Volume1.20M
Beta0.92
RSI29.97
Gross Margin96.32%
Abbisko Cayman Limited — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
Jan 13 2026
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Dec 22 2025
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
Jun 16 2025
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
Jun 10 2025
Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT
Community Chat
Ask AI
Try asking
Google Übersetzer